{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:52:56Z","timestamp":1791377576224,"version":"4.3.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150\u00a0mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88\u20131.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Identifier<\/jats:title>\n                    <jats:p>NCT00869401.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf156","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:58:36Z","timestamp":1751011116000},"page":"2661-2670","source":"Crossref","is-referenced-by-count":7,"title":["Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-2398","authenticated-orcid":false,"given":"William G","family":"Breen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G","family":"Dixon","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-9726","authenticated-orcid":false,"given":"S Keith","family":"Anderson","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic , Rochester, MN ,","place":["USA"]},{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N","family":"Sarkaria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani","family":"Kizilbash","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Galanis","sequence":"additional","affiliation":[{"name":"Office of the Alliance Group Chair, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Anderson","sequence":"additional","affiliation":[{"name":"Regions Hospital, Metro Minnesota Community Oncology Research Consortium , St Louis Park, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of Oncology, Washington University - Siteman Cancer Center , Saint Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Mazurczak","sequence":"additional","affiliation":[{"name":"Sanford NCI Community Oncology Research Program of the North Central Plains , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]},{"name":"Department of Medical Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois J","family":"Geoffroy","sequence":"additional","affiliation":[{"name":"Illinois Oncology Research Associates , Peoria, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Leinweber","sequence":"additional","affiliation":[{"name":"East Carolina University , Greenville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia N","family":"Laack","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"10","key":"2026012603465221400_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"23","key":"2026012603465221400_CIT0002","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"11","key":"2026012603465221400_CIT0003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1541-7786.595.2.11","article-title":"SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions","volume":"2","author":"Angers-Loustau","year":"2004","journal-title":"Mol Cancer Res."},{"issue":"48","key":"2026012603465221400_CIT0004","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/sj.onc.1208079","article-title":"The interplay between Src family kinases and receptor tyrosine kinases","volume":"23","author":"Bromann","year":"2004","journal-title":"Oncogene."},{"issue":"19 Pt 1","key":"2026012603465221400_CIT0005","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2026012603465221400_CIT0006","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ijrobp.2005.11.014","article-title":"SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation","volume":"64","author":"Cuneo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"21","key":"2026012603465221400_CIT0007","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/cncr.32340","article-title":"A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance\/North Central Cancer Treatment Group N0872","volume":"125","author":"Galanis","year":"2019","journal-title":"Cancer."},{"issue":"7","key":"2026012603465221400_CIT0008","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/neuonc\/nov011","article-title":"Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)","volume":"17","author":"Lassman","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026012603465221400_CIT0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-018-2791-y","article-title":"Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors","volume":"138","author":"Robison","year":"2018","journal-title":"J Neurooncol."},{"issue":"1","key":"2026012603465221400_CIT0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics."},{"issue":"1","key":"2026012603465221400_CIT0011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/neuonc\/noab158","article-title":"A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma","volume":"24","author":"Alhalabi","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026012603465221400_CIT0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1479-5876-6-53","article-title":"Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines","volume":"6","author":"Eustace","year":"2008","journal-title":"J Transl Med."},{"issue":"32","key":"2026012603465221400_CIT0013","doi-asserted-by":"crossref","first-page":"20739","DOI":"10.1016\/S0021-9258(17)32054-9","article-title":"Activation of Src-like p56\/p53lyn tyrosine kinase by ionizing radiation","volume":"269","author":"Kharbanda","year":"1994","journal-title":"J Biol Chem."},{"issue":"9","key":"2026012603465221400_CIT0014","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.molonc.2015.06.001","article-title":"Src family kinases differentially influence glioma growth and motility","volume":"9","author":"Lewis-Tuffin","year":"2015","journal-title":"Mol Oncol."},{"issue":"35","key":"2026012603465221400_CIT0015","doi-asserted-by":"crossref","first-page":"14164","DOI":"10.1073\/pnas.1211962109","article-title":"Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240","volume":"109","author":"Fenton","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2026012603465221400_CIT0016","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s10637-011-9732-3","article-title":"Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies","volume":"30","author":"Argiris","year":"2012","journal-title":"Invest New Drugs."},{"issue":"6","key":"2026012603465221400_CIT0017","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00280-019-03805-6","article-title":"A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors","volume":"83","author":"Mettu","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2026012603465221400_CIT0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10428190802563363","article-title":"Dasatinib in relapsed or plateau-phase multiple myeloma","volume":"50","author":"Wildes","year":"2009","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"2026012603465221400_CIT0019","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2026012603465221400_CIT0020","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood."},{"issue":"7","key":"2026012603465221400_CIT0021","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/neuonc\/nov086","article-title":"Dasatinib in recurrent glioblastoma: Failure as a teacher","volume":"17","author":"Schiff","year":"2015","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026012603465221400_CIT0022","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","article-title":"Efficacy of adding veliparib to temozolomide for patients with MGMT-Methylated glioblastoma: A randomized clinical trial","volume":"10","author":"Sarkaria","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"2026012603465221400_CIT0023","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1535-7163.MCT-17-0600","article-title":"Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier","volume":"17","author":"Kim","year":"2018","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"2026012603465221400_CIT0024","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026012603465221400_CIT0025","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026012603465221400_CIT0026","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2021.01.033","article-title":"A phase 2 study of Dose-intensified chemoradiation using biologically based target volume definition in patients with newly diagnosed glioblastoma","volume":"110","author":"Kim","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2026012603465221400_CIT0027","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 trial of (18)F-DOPA PET-Guided Dose-Escalated radiation therapy for glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2026012603465221400_CIT0028","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ijrobp.2015.02.058","article-title":"Hypercellularity components of glioblastoma identified by high b-Value Diffusion-Weighted imaging","volume":"92","author":"Pramanik","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"786","key":"2026012603465221400_CIT0029","doi-asserted-by":"crossref","first-page":"eadn6274","DOI":"10.1126\/scitranslmed.adn6274","article-title":"A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma","volume":"17","author":"Rendo","year":"2025","journal-title":"Sci Transl Med."},{"issue":"4","key":"2026012603465221400_CIT0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026012603465221400_CIT0031","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: A randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med."},{"issue":"7","key":"2026012603465221400_CIT0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"key":"2026012603465221400_CIT0033","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/neuonc\/noad179.0258","article-title":"Nrg oncology study Bn007: Randomized phase Ii\/Iii trial of ipilimiumab (Ipi) plus nivolumab (Nivo) Vs. temozolomide (Tmz) in Mgmt-unmethylated (Umgmt) newly diagnosed glioblastoma (Ngbm)","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro-Oncol."},{"issue":"11","key":"2026012603465221400_CIT0034","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026012603465221400_CIT0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf156\/63614592\/noaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2661\/63614592\/noaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2661\/63614592\/noaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:47:07Z","timestamp":1769417227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/10\/2661\/8176954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,28]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf156","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,28]]}}}